AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01347333 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy
Description: 26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)
Study NCT01708850 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban
Description: All specified in arm description. One arm study.
Study NCT03691467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate dental implant
Description: immediate dental implant placement in freshly extracted socket.
Study NCT03691467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate dental implant
Description: immediate dental implant placement in freshly extracted socket.
Study NCT00631670 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 15 Gy in one treatment
Study NCT00631670 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Dose: 70 Gy at 2.8 Gy/treatment
Study NCT04008342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory intervention
Description: The intervention group (IG) was submitted to 16 individual multisensory stimulation sessions that followed the protocol. In each session, at least two senses are stimulated in a safe, quiet and confidential environment. The sessions lasted 30 minutes and were conducted twice a week, on the same day and time whenever possible. Nonetheless, the session could be interrupted when the participant wished or if the therapist observed that the patient was uncomfortable. A nondirective approach and one-to-one intervention were adopted.
Study NCT02325700 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic repair
Description: Aortic bypass
Study NCT00551564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Description: Rosiglitazone tablets 4 mg dose will be administered orally by subjects
Study NCT04558216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: 20 mg tablets administered orally
Study NCT04558216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg (Two 300 mg capsules)
Study NCT02203136 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue Biopsy
Description: During bladder cancer surgery, tissue specimen taken for molecular profiling.
Study NCT02203136 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: 3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
Study NCT03691467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: topical application of hyaluronic acid
Study NCT00639873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: 2 or 4 mg/kg/day for 7 days
Study NCT00639873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinine-doxycycline
Description: quinine-doxycycline for 7 days
Study NCT02866890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction
Description: Laryngeal Tube Suction Measurement of leak pressure
Study NCT03717766 — intervention group
Intervention type: DEVICE
Intervention: intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology
Description: 5-aminolevulinic acid (5-ALA) is a pro-drug that causes fluorescent protoporphyrins that accumulate in malignant gliomas. Fluorescence can be visualized during surgery by the use of a modified microscope, which helps the surgeon define the margins of the tumor.~Neuro-navigated intraoperative ultrasound is an imaging technique that allows us to visualize intracranial lesions during surgery and correlate them with the image provided by the neuronavigator, obtaining a real-time view of the lesion and possible tumor remains.~To achieve greater tumor resections without increasing the incidence of neurological deficits, the use of intraoperative neuromonitoring has been progressively implemented. This technology and specifically the brain mapping allows us to locate the functional areas of the brain and perform more aggressive resections with lower morbidity
Study NCT00961090 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aminolevulinic Acid
Description: 20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery
Study NCT03973619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Labial Graft
Description: As replacement of the damaged urethral tissue, we used a buccal mucosa graft (labial graft).
Study NCT03973619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Jugal Graft
Description: As replacement of the damaged urethral tissue, we used a buccal mucosa graft(inner cheek - jugal graft).
Study NCT03882333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: 30 min acute exercise (bicycle at stationary cycle)
Study NCT03602131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30 mg oral twice weekly for 2 weeks
Study NCT03602131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 6 mg/m2 intravenously once daily for 5 days
Study NCT03602131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 2500 mg/m2 intravenously twice weekly for 1 week
Study NCT03602131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2 mg/kg intravenously once daily for 4 days
Study NCT03602131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
Study NCT02844946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Contextually focused form of cognitive behavioral psychotherapy that uses MINDFULNESS and behavioral activation to increase patients' psychological flexibility in areas such as ability to engage in values-based, positive behaviors while experiencing difficult thoughts, emotions, or sensations.
Study NCT06061510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids
Description: Participants in the intervention group took fish oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
Study NCT06061510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Description: Participants in the placebo group took corn oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
Study NCT03640260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing regulation with physical activity
Description: The subjects will have education leaflets with breathing and oximetry level evaluation training.
Study NCT02071004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: IV of 6 mg given once over 30 minutes
Study NCT02710578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
Study NCT02710578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
Study NCT01808144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad
Description: Tablets, 400 mg once daily (QD)
Study NCT01808144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad
Description: Tablets, 200 mg QD
Study NCT01808144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat
Description: Tabletsm 80 mg QD
Study NCT01138098 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular, single dose
Study NCT01138098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular, single dose
Study NCT01919255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picolight + Coolprep
Description: Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]
Study NCT01919255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picolight + Clicolon
Description: Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]
Study NCT00068718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Given IV
Study NCT01398345 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Respiratory Training
Description: Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
Study NCT03119532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receive metric feedback email
Description: If the provider received an email about the participants performance metrics
Study NCT01785784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF Gel
Study NCT01104857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diaphragm muscle biopsy
Description: Biopsy is obtained for biochemical analysis
Study NCT01104857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm muscle biopsy
Description: Biopsy is obtained for biochemical analysis
Study NCT03591978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of Circulating Pulmonary Cells in peripheral blood
Description: Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)
Study NCT00289458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.
Study NCT00289458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2
Description: Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.
Study NCT00289458 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: no exercise
Study NCT03360201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuko Pamoja, We are Together in Kiswahili
Description: Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context.
Study NCT03158259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehospital diagnosis and treatment
Description: The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
Study NCT03158259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehospital diagnosis and treatment
Description: The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
Study NCT00782002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-18F1
Description: Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
Study NCT02071004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Dispersible tablet, 300mg \& 75 mg, once daily for 5 days
Study NCT01210391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey infant formula
Description: New hydrolyzed infant formula.
Study NCT01210391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extensively hydrolyzed casein infant formula
Description: Commercially available infant formula.
Study NCT01016769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus + Weekly Paclitaxel + Carboplatin
Description: Temsirolimus Per dose escalation scheme Level 1 (15 mg) 2 (20 mg) Level 3 (25 mg) IVPB 30 minutes weekly (3 weeks on, 1 week off) days 1 and 8.~Paclitaxel 80 mg/m2 IVPB 1 hour weekly (2 weeks on, 1 week off) days 1 and 8. Carboplatin AUC 1.5 IVPB 30 minutes days 1 and 8. On Day 15 of each cycle, patients begin the rest week.
Study NCT00344786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNF2024 (BIIB021)
Description: Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment.
Study NCT03788837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILOPROST
Description: The patient will receive treatment with intravenous ILOPROST therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.
Study NCT03788837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h
Study NCT01189916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopically assisted Appendectomy Surgery
Description: Using endoscopic instruments a small incision will be made in the rectum wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The appendix will be removed through the anus. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the rectal access site.
Study NCT01015391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2
Description: 1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops
Study NCT01015391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
Study NCT00960466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Thermometer and Problems List
Description: When using the distress thermometer and problem list (DT\&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT\&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
Study NCT00960466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual psychosocial support
Description: If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
Study NCT01654549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.pylori eradication
Description: Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
Study NCT03768167 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Posterolateral corpectomy
Description: Investigators' goal in this study is to report clinical series of 26 patients in Sohag university hospital with dorsolumbar metastatic lesions from different primaries treated by single-stage posterolateral circumferential corpectomy with reconstruction by a pyramesh titanium cage and account the degree of improvement regarding the pain.
Study NCT01587508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meloxicam/cyclobenzaprine hydrochloride
Description: two oral capsules a day during approximately 07 days
Study NCT01587508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meloxicam - Movatec®
Description: two oral tablet a day during approximately 07 days
Study NCT01587508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclobenzaprine - Miosan®
Description: two oral tablet a day during approximately 07 days
Study NCT04910893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytokine Adsorption
Description: Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.
Study NCT04910893 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard intensive care of patients suffering septic shock
Study NCT03048851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low dosage SES group
Description: The participants were randomly assigned to one of the five intervention groups. Low dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 45 minutes and arm with wrap for 45 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
Study NCT03048851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dosage SES group
Description: The participants were randomly assigned to one of the five intervention groups. High dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 90 minutes and arm with wrap for 90 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.